The present invention relates to Tapinarof dimethylacetamide solvate and crystalline forms thereof, processes for preparation and pharmaceutical compositions thereof. Furthermore, the invention concerns its use for the preparation of a medicament, preferably for the treatment of skin diseases.
C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
The present invention refers to a process for preparing sucrose octasulfate octakistriethylammonium salt (TASOS) powder, comprising the steps of combining a TASOS solution with a polar organic solvent(s) and triethylamine, thereby obtaining a TASOS solution, the polar organic solvent(s), and triethylamine; concentrating said TASOS solution; combining it with 2-methyltetrahydrofuran and/or tetrahydrofuran and triethylamine, thereby obtaining a mixture; and stirring said mixture until a white TASOS powder is obtained.
The present invention refers to a process for preparing sucrose octasulfate octakistriethylammonium salt (TASOS) powder, comprising the steps of combining a TASOS solution with a polar organic solvent(s) and triethylamine, thereby obtaining a TASOS solution, the polar organic solvent(s), and triethylamine; concentrating said TASOS solution; combining it with 2-methyltetrahydrofuran and/or tetrahydrofuran and triethylamine, thereby obtaining a mixture; and stirring said mixture until a white TASOS powder is obtained.
The present invention also refers to a sucrose octasulfate octakistriethylammonium salt (TASOS) powder having a purity of at least 96%, the use of the sucrose octasulfate octakistriethylammonium salt (TASOS) powder for preparing a pharmaceutical composition, and the use of tetrahydrofuran or 2-methyltetrahydrofuran as antisolvent for the preparation of TASOS powder.
The present invention refers to a process for preparing sucrose octasulfate octakistriethylammonium salt (TASOS) powder, comprising the steps of combining a TASOS solution with a polar organic solvent(s) and triethylamine, thereby obtaining a TASOS solution, the polar organic solvent(s), and triethylamine; concentrating said TASOS solution; combining it with 2-methyltetrahydrofuran and/or tetrahydrofuran and triethylamine, thereby obtaining a mixture; and stirring said mixture until a white TASOS powder is obtained.
The present invention also refers to a sucrose octasulfate octakistriethylammonium salt (TASOS) powder having a purity of at least 96%, the use of the sucrose octasulfate octakistriethylammonium salt (TASOS) powder for preparing a pharmaceutical composition, and the use of tetrahydrofuran or 2-methyltetrahydrofuran as antisolvent for the preparation of TASOS powder.
Finally, the present invention refers to a pharmaceutical composition prepared by using the sucrose octasulfate octakistriethylammonium salt (TASOS) powder of the present invention, and to the pharmaceutical composition for use in treating cancer.
The present invention relates to solid-state forms of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide methane sulfonic acid (INN: belumosudil mesylate) and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising a solid-state form of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of autoimmune diseases such as graft-versus-host disease (GvHD) and systemic sclerosis.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
19.
MANDELATE FORM OF 1-(4-(((6-AMINO-5-(4-PHENOXYPHENYL)PYRIMIDIN-4-YL)AMINO)METHYL)PIPERIDIN-1-YL)PROP-2-EN-1-ONE
The present invention relates to a mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl) pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one (INN: evobrutinib) and a process of producing the same. Furthermore, the invention relates to a pharmaceutical composition comprising the mandelate form of evobrutinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of multiple sclerosis.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention relates to aqueous high protein concentration compositions, particularly pharmaceutical compositions. The pharmaceutical compositions are useful for delivery of high concentration of the protein active ingredient, such as an antibody, to a patient without high levels of protein aggregation, or other destabilizing factors. The compositions of the invention comprise about 100 mg/mL or more of protein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to a method and device which allows in real-time the determination of concentration, purity and potency of a biological product during purification and/or concentration processes in order to intervene into the process, either for process control or real time release. The properties of the process stream are continuously monitored by at least two online sensors and with the aid of multivariate statistical analysis so that concentration, purity and potency is determined in real time.
G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
G05B 19/418 - Total factory control, i.e. centrally controlling a plurality of machines, e.g. direct or distributed numerical control [DNC], flexible manufacturing systems [FMS], integrated manufacturing systems [IMS] or computer integrated manufacturing [CIM]
The present invention relates to a crystalline form of sotorasib and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of sotorasib of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of a cancer with a KRAS mutation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques à usage humain pour la prévention et le traitement du système nerveux central, à savoir infections du système nerveux central, maladies cérébrales, troubles du mouvement du système nerveux central, troubles de la motilité oculaire, maladies de la moelle épinière; préparations pharmaceutiques à usage humain pour la prévention et le traitement de maladies immunologiques, à savoir maladies auto-immunes, syndromes d'immunodéficience; préparations pharmaceutiques à usage humain pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques à usage humain pour la prévention et le traitement de diabètes; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles métaboliques, à savoir diabète, obésité, hyperlipidémie, résistance à l'insuline, syndrome métabolique; anti-inflammatoires à usage humain; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles du système respiratoire; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles du système musculo-squelettique, à savoir maladies du tissu conjonctif, maladies osseuses, maladies rachidiennes, douleurs dorsales, fractures, entorses, blessures cartilagineuses; préparations pharmaceutiques à usage humain pour la prévention et le traitement de maladies génito-urinaires, à savoir maladies urologiques, infertilité, maladies sexuellement transmissibles, maladies pelviennes inflammatoires; préparations pharmaceutiques à usage humain à utiliser en dermatologie, à savoir pour les dermatites, les maladies de pigmentation de la peau, les maladies sexuellement transmissibles; préparations pharmaceutiques à usage humain utilisées en oncologie; préparations pharmaceutiques à usage humain à utiliser en hématologie, à savoir pour le traitement de troubles sanguins; préparations pharmaceutiques à usage humain utilisées dans le cadre de la transplantation d'organes et de tissus; préparations pharmaceutiques à usage humain utilisées en ophtalmologie; préparations pharmaceutiques à usage humain utilisées en gastro-entérologie; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles et maladies oculaires; anti-infectieux à usage humain, antibactériens à usage humain, antiviraux à usage humain, antibiotiques à usage humain, antifongiques systémiques et topiques à usage humain.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives for human use; anti-inflammatories for human use; antibacterial pharmaceutical preparations for human use; antibiotics for human use; antifungal preparations for human use; antivirals for human use; cardiovascular pharmaceutical preparations for human use; dermatological pharmaceutical preparations for human use; pharmaceutical preparations for human use for inhaling for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations for human use acting on the central nervous system; pharmaceutical preparations and substances for human use for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for human use, used in hematology and in tissue and organ transplantation; pharmaceutical preparations for human use for the prevention and treatment of eye diseases; pharmaceutical preparations for human use for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders related to the immune system; pharmaceutical preparations for human use for the prevention and treatment of kidney diseases; pharmaceutical preparations for human use for the prevention and treatment of diabetes; pharmaceutical preparations for human use for the prevention and treatment of hypertension; pharmaceutical preparations for human use for the prevention and treatment of skin conditions; pharmaceutical preparations for human use, used in dermatology; pharmaceutical preparations for human use, used in urology; pharmaceutical preparations for human use, used in ophthalmology; pharmaceutical preparations for human use for the prevention and treatment of cancer and tumors; pharmaceutical preparations for human use for the prevention and treatment of allergies; pharmaceutical preparations for human use for the prevention and treatment of bone diseases; pharmaceutical preparations for human use for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques à usage humain pour la prévention et le traitement du système nerveux central, à savoir infections du système nerveux central, maladies cérébrales, troubles du mouvement du système nerveux central, troubles de la motilité oculaire, maladies de la moelle épinière; préparations pharmaceutiques à usage humain pour la prévention et le traitement de maladies immunologiques, à savoir maladies auto-immunes, syndromes d'immunodéficience; préparations pharmaceutiques à usage humain pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques à usage humain pour la prévention et le traitement de diabètes; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles métaboliques, à savoir diabète, obésité, hyperlipidémie, résistance à l'insuline, syndrome métabolique; anti-inflammatoires à usage humain; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles du système respiratoire; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles du système musculo-squelettique, à savoir maladies du tissu conjonctif, maladies osseuses, maladies rachidiennes, douleurs dorsales, fractures, entorses, blessures cartilagineuses; préparations pharmaceutiques à usage humain pour la prévention et le traitement de maladies génito-urinaires, à savoir maladies urologiques, infertilité, maladies sexuellement transmissibles, maladies pelviennes inflammatoires; préparations pharmaceutiques à usage humain à utiliser en dermatologie, à savoir pour les dermatites, les maladies de pigmentation de la peau, les maladies sexuellement transmissibles; préparations pharmaceutiques à usage humain utilisées en oncologie; préparations pharmaceutiques à usage humain à utiliser en hématologie, à savoir pour le traitement de troubles sanguins; préparations pharmaceutiques à usage humain utilisées dans le cadre de la transplantation d'organes et de tissus; préparations pharmaceutiques à usage humain utilisées en ophtalmologie; préparations pharmaceutiques à usage humain utilisées en gastro-entérologie; préparations pharmaceutiques à usage humain pour la prévention et le traitement de troubles et maladies oculaires; anti-infectieux à usage humain, antibactériens à usage humain, antiviraux à usage humain, antibiotiques à usage humain, antifongiques systémiques et topiques à usage humain.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives for human use; anti-inflammatories for human use; antibacterial pharmaceutical preparations for human use; antibiotics for human use; antifungal preparations for human use; antivirals for human use; cardiovascular pharmaceutical preparations for human use; dermatological pharmaceutical preparations for human use; pharmaceutical preparations for human use for inhaling for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations for human use acting on the central nervous system; pharmaceutical preparations and substances for human use for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for human use, used in hematology and in tissue and organ transplantation; pharmaceutical preparations for human use for the prevention and treatment of eye diseases; pharmaceutical preparations for human use for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders related to the immune system; pharmaceutical preparations for human use for the prevention and treatment of kidney diseases; pharmaceutical preparations for human use for the prevention and treatment of diabetes; pharmaceutical preparations for human use for the prevention and treatment of hypertension; pharmaceutical preparations for human use for the prevention and treatment of skin conditions; pharmaceutical preparations for human use, used in dermatology; pharmaceutical preparations for human use, used in urology; pharmaceutical preparations for human use, used in ophthalmology; pharmaceutical preparations for human use for the prevention and treatment of cancer and tumors; pharmaceutical preparations for human use for the prevention and treatment of allergies; pharmaceutical preparations for human use for the prevention and treatment of bone diseases; pharmaceutical preparations for human use for the prevention and treatment of respiratory diseases and asthma
The present invention relates to a novel crystal of ensifentrine free base and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said ensifentrine free base crystal, at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and symptoms of a COVID-19 infection.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques utilisées en dermatologie, à savoir la dermatite, les maladies affectant la pigmentation de la peau, les maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisées pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques utilisées en dermatologie, à savoir la dermatite, les maladies affectant la pigmentation de la peau, les maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisées pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
58.
Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids
The present invention is directed to a parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of specific liquids in specific amounts, respectively.
The invention relates to particles comprising odevixibat in a non-crystalline form and to a process for the preparation thereof. The invention further relates to a pharmaceutical composition and/or oral dosage form of odevixibat comprising a plurality of said particles. The particles and the pharmaceutical composition can be used as a medicament, e.g. in the treatment of liver diseases. The invention further relates to odevixibat-2-pentanol solvate which is useful for the preparation of particles comprising odevixibat in a non-crystalline form, a process for the preparation thereof, and to the use of odevixibat-2-pentanol solvate for the preparation of particles comprising odevixibat in a non-crystalline form.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure
The present invention relates to an inhaler device for use with an elongate strip medicament carrier comprising a base with a plurality of medicament pockets or blisters and a peelable lidding sheet covering the blisters, the inhaler device comprising; an indexer movable in a first direction to advance a blister pocket into an inhalation position; an opening system for peeling the peelable lidding sheet from the base to expose medicament within each medicament pocket; the opening system comprising a peel management component movable in a first direction corresponding to said first direction of the indexer to delay the peeling action when the indexer is advanced, and in a second, opposite, direction to allow the lidding sheet to be peeled from the base; wherein the indexer and peel management component are separately driven in said first direction so that movement of the indexer does not dictate movement of the peel management component.
The present invention refers to a process for preparing sucrose octasulfate octakistriethylammonium salt (TASOS) powder, comprising the steps of combining a TASOS solution with a polar organic solvent(s) and triethylamine, thereby obtaining a TASOS solution, the polar organic solvent(s), and triethylamine; concentrating said TASOS solution; combining it with 2-methyltetrahydrofuran and/or tetrahydrofuran and triethylamine, thereby obtaining a mixture; and stirring said mixture until a white TASOS powder is obtained. The present invention also refers to a sucrose octasulfate octakistriethylammonium salt (TASOS) powder having a purity of at least 96%, the use of the sucrose octasulfate octakistriethylammonium salt (TASOS) powder for preparing a pharmaceutical composition, and the use of tetrahydrofuran or 2-methyltetrahydrofuran as antisolvent for the preparation of TASOS powder. Finally, the present invention refers to a pharmaceutical composition prepared by using the sucrose octasulfate octakistriethylammonium salt (TASOS) powder of the present invention, and to the pharmaceutical composition for use in treating cancer.
23233 by weight, and wherein the pharmaceutical formulation comprises an oxidation-sensitive compound. The invention also relates to a medical device comprising such glass container as well as to a method of producing such glass container.
09 - Scientific and electric apparatus and instruments
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Software in the field of pharmaceutical products related to multiple sclerosis therapy. Telecommunication services; providing access to databases; providing access to electronic communication networks; podcasting; all the before in the field of pharmaceutical products related to multiple sclerosis therapy. Education, training and entertainment services in the field of pharmaceutical products related to multiple sclerosis therapy. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; all the before in the field of pharmaceutical products related to multiple sclerosis therapy. Medical services in the field of pharmaceutical products related to multiple sclerosis therapy.
Protective capsules for vials for medical use; plastic protection for vials for medical use; vials for medical use; medical and surgical devices, specially adapted for glass vials and containers for medical use.
The present invention relates to a crystalline form of acoramidis hydrochloride and a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of acoramidis hydrochloride of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of TTR amyloidosis (ATTR).
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical products for scientific purposes; chemical
substances and raw materials for manufacturing medicines. Pharmaceutical preparations for human use; dietetic food and
substances for medical and human use; food supplements for
humans. Wholesale and retail sale; advertising, marketing and
promotion; company assistance, management and administrative
services; all the aforesaid services in the field of
chemical substances and raw materials for manufacturing
medicines, pharmaceutical preparations for human use,
dietetic food and preparations for medical and human use,
and food supplements for humans. Treating materials, namely, combining chemical substances
and raw materials for manufacturing medicines,
pharmaceutical preparations for human use, dietetic food and
preparations for medical and human use, and food supplements
for humans; rental of equipment for manufacturing and
assembling chemical substances and raw materials for
manufacturing medicines, pharmaceutical preparations for
human use, dietetic food and preparations for medical and
human use, and food supplements for humans. Quality analysis and control in the field of chemical
substances and raw materials for manufacturing medicines,
pharmaceutical preparations for human use, dietetic food and
preparations for medical and human use and food supplements
for humans.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques utilisées en dermatologie, à savoir la dermatite, les maladies affectant la pigmentation de la peau, les maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisée pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
The present invention relates to a mandelate form of 1-(4-(((6-amino-5-(4- phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one (INN: evobrutinib) and a process of producing the same. Furthermore, the invention relates to a pharmaceutical composition comprising the mandelate form of evobrutinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of multiple sclerosis.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to solid-state forms of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin- 2-yl)phenoxy)-N-isopropylacetamide methane sulfonic acid (INN: belumosudil mesylate) and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising a solid-state form of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of autoimmune diseases such as graft-versus-host disease (GvHD) and systemic sclerosis.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Auto-injecteurs pré-remplis de préparations pharmaceutiques pour le traitement du diabète.
(2) Dispositifs d'injection pour produits pharmaceutiques, nommément instruments d'injection sans aiguilles, injecteurs à usage médical, injecteurs d'insuline et seringues pour injection; dispositifs pour l'injection de produits pharmaceutiques, à savoir seringues, injecteurs à usage médical, injecteurs d'insuline et seringues pour injection.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Auto-injecteurs pré-remplis de préparations pharmaceutiques pour le traitement de diabète.
(2) Dispositifs d'injection pour produits pharmaceutiques, nommément instruments d'injection sans aiguilles, injecteurs à usage médical, injecteurs d'insuline et seringues pour injection; dispositifs pour l'injection de produits pharmaceutiques, à savoir seringues, injecteurs à usage médical, injecteurs d'insuline et seringues pour injection.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Auto-injectors prefilled with pharmaceutical preparations for diabetes treatment Injection devices for pharmaceutical products, namely, injection instruments without needles, injectors for medical use, insulin injectors and syringes for injections; devices for injecting pharmaceutical products, namely, syringes, injectors for medical use, insulin injectors and syringes for injections
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Autoinjectors prefilled with pharmaceutical preparations for treating diabetes Injection devices for pharmaceutical products, namely, injection instruments without needles, injectors for medical use, insulin injectors sold empty and syringes for injections; devices for injecting pharmaceutical products, namely, syringes, injectors for medical use, insulin injectors sold empty and syringes for injections
The present invention relates to a crystalline form of sotorasib and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of sotorasib of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of a cancer with a KRAS mutation.
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Trace elements for injection, namely, dietetic infusions for medical use containing copper, chromium, zinc, selenium, manganese, iron, iodine, fluoride and molybdenum for parenteral infusion
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma; all the aforesaid goods for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques utilisées en dermatologie, à savoir la dermatite, les maladies affectant la pigmentation de la peau, les maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisées pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
The present invention relates to dose counting mechanisms for medicament inhaler devices, for example metered-dose inhaler (MDI) devices. In particular, the invention relates to a counter comprising a counting component (20,620), a locking element (46,646) for resisting movement of the counting component (20,620), and a distinct driving element (70,670) for driving movement of the counting component (20,620). The locking and driving elements are actuated by movement of a common element to move the locking element (46,646) out of engagement with the counting component (20,620) and to move the driving element (70,670). The driving element (70,670) applies a motive force to the counting component (20,620) before the locking element (46,646) fully disengages from the counting component (20,620).
The present invention relates to controlling the amount of by-products resulting from N- terminal truncation of a polypeptide expressed in a host cell. In particular, the present invention relates to method of producing a recombinant polypeptide, in particular rhG-CSF or recombinant antibodies, with reduced impurities resulting from N-terminal truncation of said recombinant polypeptide.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
